antimicrobial resistance

Infections that resist existing antibiotics, and new antibiotics and phage therapies against them.

Theme · 2 companies · 1 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ARMP Armata Pharmaceuticals, Inc.

    In development“We see bacteriophages as a potentially safer and effective alternative to antibiotics and an essential response to the growing bacterial resistance to current classes of antibiotics.”

    Latest 10-QQ3 FY2026NegativeBankruptcy / going concern ·

    AP-SA02 advances toward Phase 3 with FDA support and expanded MTEC funding, but a cash shortfall threatens development.

    • Revenue$3.2MYoY +173.6%
    • Net income$54.9Mvs −$26.7M year ago
  • INVA Innoviva, Inc.

    Sells it 18%, $74.4M a year“The product is a combination of sulbactam, a β-lactam antibiotic, and durlobactam, a novel β-lactamase inhibitor (“BLI”) with broad spectrum β-lactamase coverage including Classes A, C and D, that was specifically developed for the treatment of a variety of serious infections caused by carbapenem-resistant Acinetobacter”

    Latest 10-QQ3 FY2026Positive ·

    XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings

    • Revenue$106.1MYoY −1.6%
    • Net income−$73.9Mvs $89.9M year ago

Feedback